行业洞察美国 FDAT1064
Masuu Global Solutions LLC, U.S. Agent for Extrovis AG, et al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications; Correction
🤖 AI 摘要
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 20, 2026. The document announced the withdrawal of approval of 11 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of March 23, 2026. The document indicated that FDA was withdrawing approval of ANDAs 078022 for propranolol hydrochloride (HCl), extended- release capsule, 60 milligrams (mg), 80 mg, 120 mg, and 160 mg, and 090665 for lidocaine HCl, injectab
分析模型：rule-based-v3 · 07-09 06:59
评分详情
综合分 64/100
信源权威
95
影响范围
70
时效性
50
合规紧急
40
行业关注
35
Federal Register: FDA Notices (官方通知)
操作：